Sean Wharton, leader of the Wharton Medical Clinic for Weight and Diabetes Management in Ontario, Canada.Researchers tested the triple-dose of semaglutide in two clinical trials, one involving people with obesity and the other in people with obesity and type 2 diabetes.In both trials, participants were randomly assigned to receive either placebo injections or injections of 2.4 mg or 7.4 mg of semaglutide for 72 weeks.In adults without diabetes, a 7.2 mg dose of semaglutide caused an average weight loss of nearly 19%, surpassing the 16% seen with the 2.4 mg dose and 4% with placebo.Nearly half of the people on the higher dose lost 20% or more of their body weight, with one-third losing at least 25%, researchers reported.Adults with type 2 diabetes had similar results 13% weight loss on the heavier dose versus 10% on the lighter dose and 4% with placebo.Participants on the higher dose also achieved trimmer waistlines and lower blood pressure, blood sugar and cholesterol, results showed.Both trials also reported that the higher dose of semaglutide was safe and generally well tolerated

The tirzepatide vs semaglutide side effects comparison shows tirzepatide generally has a comparable safety profile to other GLP-1 class medications
Ive probably had a dozen patients in the past month who have started the conversation with me about peptides, she says
At the same time, TB-500 activates actin polymerization, a cytoskeletal protein, allowing fibroblasts and endothelial cells to migrate extremely rapidly through these newly formed pathways directly to the site of injury
Both TB-500 and BPC-157 may also support angiogenesis
The absence of receptor downregulation or tolerance development in research suggests sustained effectiveness without the need for dose escalation over time